Silvio Danese focuses on Internal medicine, Ulcerative colitis, Inflammatory bowel disease, Crohn's disease and Immunology. His Internal medicine research incorporates elements of Gastroenterology, Placebo and Surgery. His work on Randomized controlled trial and Clinical endpoint is typically connected to Maintenance therapy as part of general Surgery study, connecting several disciplines of science.
His work carried out in the field of Ulcerative colitis brings together such families of science as Young adult, Colitis and Intensive care medicine. His biological study spans a wide range of topics, including Tumor necrosis factor alpha and Cancer research. His Crohn's disease study combines topics from a wide range of disciplines, such as Prospective cohort study, Clinical trial, Radiology and Cohort study.
Silvio Danese mainly investigates Internal medicine, Ulcerative colitis, Inflammatory bowel disease, Crohn's disease and Gastroenterology. His study in the field of Vedolizumab, Infliximab, Adalimumab and Adverse effect also crosses realms of In patient. His Ulcerative colitis research is multidisciplinary, incorporating elements of Placebo, Tofacitinib, Colitis and Ustekinumab.
The study incorporates disciplines such as Immunology and Intensive care medicine in addition to Inflammatory bowel disease. His Crohn's disease study incorporates themes from Magnetic resonance imaging, Clinical trial, Surgery and Cohort study. His Gastroenterology study frequently draws connections between adjacent fields such as Colonoscopy.
The scientist’s investigation covers issues in Internal medicine, Ulcerative colitis, Inflammatory bowel disease, Gastroenterology and Crohn's disease. His Vedolizumab, Ustekinumab, Adverse effect and Adalimumab study in the realm of Internal medicine interacts with subjects such as In patient. Silvio Danese interconnects Tofacitinib, Colitis, Bioinformatics and Surrogate endpoint in the investigation of issues within Ulcerative colitis.
The various areas that Silvio Danese examines in his Inflammatory bowel disease study include Inflammation and Intensive care medicine. His work deals with themes such as Biopsy, Endoscopy and Ultrasound, which intersect with Gastroenterology. His studies deal with areas such as Dermatology and Colonoscopy as well as Crohn's disease.
His main research concerns Inflammatory bowel disease, Internal medicine, Ulcerative colitis, Crohn's disease and Gastroenterology. His Inflammatory bowel disease study results in a more complete grasp of Disease. The Cohort, Ustekinumab, Prospective cohort study and Clinical trial research Silvio Danese does as part of his general Internal medicine study is frequently linked to other disciplines of science, such as Maintenance therapy, therefore creating a link between diverse domains of science.
The concepts of his Ulcerative colitis study are interwoven with issues in Colitis, Adverse effect, Ultrasound, Magnetic resonance imaging and Diarrhea. Many of his research projects under Crohn's disease are closely connected to Patient-reported outcome with Patient-reported outcome, tying the diverse disciplines of science together. His Gastroenterology research is multidisciplinary, relying on both Biomarker, Biopsy, Balance and Magnetic resonance enterography.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Brian G Feagan;Paul Rutgeerts;Bruce E Sands;Stephen Hanauer.
The New England Journal of Medicine (2013)
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
A. Dignass;G. Van Assche;J.O. Lindsay;M. Lémann.
Journal of Crohns & Colitis (2010)
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
L. Peyrin-Biroulet;W. Sandborn;B. E. Sands;W. Reinisch;W. Reinisch.
The American Journal of Gastroenterology (2015)
Epithelial NEMO links innate immunity to chronic intestinal inflammation
Arianna Nenci;Christopher Becker;Andy Wullaert;Ralph Gareus.
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
William J. Sandborn;Chinyu Su;Bruce E. Sands;Geert R. D’Haens.
The New England Journal of Medicine (2017)
Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.
Remo Panaccione;Subrata Ghosh;Stephen Middleton;Juan R. Márquez.
Tolerogenic dendritic cells: cytokine modulation comes of age
Sergio Rutella;Silvio Danese;Giuseppe Leone.
EXTRAINTESTINAL MANIFESTATIONS IN INFLAMMATORY BOWEL DISEASE
Silvio Danese;Stefano Semeraro;Alfredo Papa;Italia Roberto.
World Journal of Gastroenterology (2005)
Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines
J. Panes;Y. Bouhnik;W. Reinisch;J. Stoker.
Journal of Crohn's and Colitis (2013)
Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial.
Julián Panés;Damián García-Olmo;Gert Van Assche;Jean Frederic Colombel.
The Lancet (2016)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: